---
aliases: >-
  /news/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77
archetype: curated-content
author:
  - Radhika Narayanan
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - >-
    Mayo Clinic research shows monoclonal antibodies reduce breakthrough
    hospitalization by 77%
categories:
  - 'Medical Subject Headings (MeSH): Allergy and Immunology'
  - 'Medical Subject Headings (MeSH): Patient Safety'
categorySlug:
  - 'medical subject headings (mesh): allergy and immunology'
  - 'medical subject headings (mesh): patient safety'
categoryUrl:
  - topic/medical-subject-headings-mesh-allergy-and-immunology
  - topic/medical-subject-headings-mesh-patient-safety
categoryLabel:
  - Allergy and Immunology
  - Patient Safety
contentCategories: netspective-medigy-news-curated-content
institution: null
offering: null
layOut: single
date: '2021-11-18'
description: >-
  Monoclonal antibodies decreased the risk of hospitalization by 77 percent
  among patients with breakthrough COVID-19, according to research published
  Nov. 16 in the Journal of Infectious Diseases.Resea
favIconImage: null
featuredImage:
  alt: >-
    Mayo Clinic research shows monoclonal antibodies reduce breakthrough
    hospitalization by 77%
  format: JPEG
  href: e679c986-2082-5c70-9f5e-733074ec584d-featuredImage.jpeg
  size:
    - 600
    - 800
  valid: true
  workPackage: 9888
  wpAttachment:
    fileName: Curated_Featured_Image.jpg
    link: /api/v3/attachments/19122/content
featuredPdf: null
htmlMetaData:
  author: Katie Adams
  description: >-
    Monoclonal antibodies decreased the risk of hospitalization by 77 percent
    among patients with breakthrough COVID-19, according to research published
    Nov. 16 in the Journal of Infectious Diseases.
  generator: null
  viewport: 'width=device-width, initial-scale=1'
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: >-
    Monoclonal antibodies decreased the risk of hospitalization by 77 percent
    among patients with breakthrough COVID-19, according to research published
    Nov. 16 in the Journal of Infectious Diseases.
  ogimage: null
  ogsite_name: null
  ogtitle: >-
    Mayo Clinic research shows monoclonal antibodies reduce breakthrough
    hospitalization by 77%
  ogtype: null
  ogupdated_time: null
  ogurl: null
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: null
  keywords: >-
    antibodies, monoclonal antibodies, vaccine, breakthrough case, COVID-19,
    coronavirus, pandemic, Eli Lilly, Regeneron, hospital, pharmacy, healthcare,
    hospitalization, infectious diseases, infectious, diseases, nov, published,
    journal
id: 9888
identifier: News
lastMod: '2021-11-18T19:59:15.839383Z'
link:
  brand: beckershospitalreview.com
  href: >-
    https://www.beckershospitalreview.com/pharmacy/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77.html
  original: >-
    https://www.beckershospitalreview.com/pharmacy/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77.html
href: >-
  https://www.beckershospitalreview.com/pharmacy/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77.html
original: >-
  https://www.beckershospitalreview.com/pharmacy/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77.html
mastHead: NEWS
mdName: e679c986-2082-5c70-9f5e-733074ec584d.md
openGraphMetaData:
  ogdescription: >-
    Monoclonal antibodies decreased the risk of hospitalization by 77 percent
    among patients with breakthrough COVID-19, according to research published
    Nov. 16 in the Journal of Infectious Diseases.
  ogtitle: >-
    Mayo Clinic research shows monoclonal antibodies reduce breakthrough
    hospitalization by 77%
  ogurl: null
  ogimage: null
  ogsite_name: null
  ogtype: null
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: >-
    https://www.beckershospitalreview.com/pharmacy/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77.html
  medigyTopics:
    - 'Medical Subject Headings (MeSH): Allergy and Immunology'
    - 'Medical Subject Headings (MeSH): Patient Safety'
  sourceUrl: >-
    https://www.beckershospitalreview.com/pharmacy/mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77.html
openProjectWorkPackageType: Curated Content
searchCategory: News
slug: >-
  beckershospitalreview-mayo-clinic-research-shows-monoclonal-antibodies-reduce-breakthrough-hospitalization-by-77
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: >-
  Mayo Clinic research shows monoclonal antibodies reduce breakthrough
  hospitalization by 77%
via: ' '
insights_description: null
insights_name: null
viaLink: null
relatedOfferings: null
twitterMetaData:
  twittercard: null
  twitterdescription: >-
    Monoclonal antibodies decreased the risk of hospitalization by 77 percent
    among patients with breakthrough COVID-19, according to research published
    Nov. 16 in the Journal of Infectious Diseases.
  twittertitle: >-
    Mayo Clinic research shows monoclonal antibodies reduce breakthrough
    hospitalization by 77%
  twitterimage: 'https://www.beckershospitalreview.com/images/channels/pharmacy/7.jpg'
  twitterurl: null
---
<p>Monoclonal antibodies decreased the risk of hospitalization by 77 percent among patients with breakthrough COVID-19, according to research published Nov. 16 in the <a href="https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab570/6429422"><i>Journal of Infectious Diseases</i></a>.</p><p>Researchers from Rochester, Minn.-based Mayo Clinic analyzed outcomes among COVID-19 patients who were fully vaccinated and received one of the following antibodies: Eli Lilly's <a href="https://www.beckershospitalreview.com/pharmacy/hhs-stops-shipping-eli-lilly-s-solo-covid-19-antibody-treatment-now-only-ships-its-antibody-cocktail.html">bamlanivimab</a>, Eli Lilly's <a href="https://www.beckershospitalreview.com/pharmacy/hhs-extends-shelf-life-of-eli-lilly-s-covid-19-antibody-drug.html">combination</a> of bamlanivimab and etesevimab, or Regeneron's <a href="https://www.beckershospitalreview.com/pharmacy/regeneron-covid-19-antibody-drug-reduces-infection-risk-82-in-clinical-trial.html">combination</a> of casirivimab and imdevimab.&nbsp;</p><p>From January to August 2021, participants received the antibodies as a single infusion. Their outcomes were compared to breakthrough COVID-19 patients who did not receive antibodies.</p><p>The hospitalization rate was 2.7 percent among patients who received antibodies, compared to 10.7 percent among those who did not receive treatment.</p><p>The participants' average age was 54, and about 10 percent were cancer patients.</p>